Sarepta Therapeutics' investment in Lexeo Therapeutics' gene therapy programs indicates a strategic move to expand its portfolio in gene therapy, particularly for cardiovascular diseases. This could potentially lead to the development of new products, which could boost Sarepta's revenues in the future. Therefore, this news is likely to have a positive impact on SRPT's stock price in the short term.